Rigel Pharmaceuticals | RIGL - Operating Expenses


Rigel Pharmaceuticals reported $117.61M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 5.69B 6B Sep/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
AstraZeneca USD 11.55B 674M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Celldex Therapeutics USD 649.47M 65.1M Sep/2026
Daiichi Sankyo JPY 483.8B 5.85B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Veracyte USD 133.73M 7.37M Sep/2026